ReShape Lifesciences Inc./$RSLS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Ticker
$RSLS
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
18
ISIN
US76090R4083
Website
RSLS Metrics
BasicAdvanced
$5.7M
-
-$96.22
1.94
-
Price and volume
Market cap
$5.7M
Beta
1.94
52-week high
$8.29
52-week low
$2.23
Average daily volume
5M
Financial strength
Current ratio
1.527
Quick ratio
0.788
Long term debt to equity
1.138
Total debt to equity
10.569
Interest coverage (TTM)
-157.43%
Profitability
EBITDA (TTM)
-6.277
Gross margin (TTM)
63.74%
Net profit margin (TTM)
-48.26%
Operating margin (TTM)
-87.76%
Effective tax rate (TTM)
-0.93%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-53.49%
Return on equity (TTM)
-120.16%
Valuation
Price to revenue (TTM)
0.012
Price to book
0.26
Price to tangible book (TTM)
0.26
Price to free cash flow (TTM)
-0.019
Free cash flow yield (TTM)
-5,246.59%
Free cash flow per share (TTM)
-12,431.23%
Growth
Revenue change (TTM)
-13.92%
3-year revenue growth (CAGR)
-17.59%
RSLS News
AllArticlesVideos
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
GlobeNewsWire·4 days ago
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
GlobeNewsWire·1 week ago
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ReShape Lifesciences Inc. stock?
ReShape Lifesciences Inc. (RSLS) has a market cap of $5.7M as of July 05, 2025.
What is the P/E ratio for ReShape Lifesciences Inc. stock?
The price to earnings (P/E) ratio for ReShape Lifesciences Inc. (RSLS) stock is 0 as of July 05, 2025.
Does ReShape Lifesciences Inc. stock pay dividends?
No, ReShape Lifesciences Inc. (RSLS) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next ReShape Lifesciences Inc. dividend payment date?
ReShape Lifesciences Inc. (RSLS) stock does not pay dividends to its shareholders.
What is the beta indicator for ReShape Lifesciences Inc.?
ReShape Lifesciences Inc. (RSLS) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.